HCM:NSD-HUTCHMED DRC (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 13.45

Change

0.00 (0.00)%

Market Cap

USD 2.33B

Volume

0.34M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


HCM Stock Forecast & Price:
Based on the HUTCHMED DRC stock forecasts from 1 analysts, the average analyst target price for HUTCHMED DRC is USD 0.00 over the next 12 months. HUTCHMED DRC’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of HUTCHMED DRC is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, HUTCHMED DRC’s stock price was USD 13.45. HUTCHMED DRC’s stock price has changed by +1.74% over the past week, +39.96% over the past month and -66.66% over the last year.

About HUTCHMED DRC (HCM:NSD)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX Neurocrine Biosciences Inc

N/A

USD9.49B 134.12 70.22
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intracellular Th

N/A

USD5.20B N/A -14.65
PCRX Pacira Pharmaceuticals Inc

N/A

USD2.63B 69.70 24.90
ALVO Alvotech Ordinary Shares

N/A

USD2.01B N/A -132.92
IRWD Ironwood Pharmaceuticals Inc

N/A

USD1.77B 3.64 7.08
AMPH Amphastar P

N/A

USD1.73B 21.04 11.71
DVAX Dynavax Technologies Corporati..

N/A

USD1.64B 16.20 10.70

ETFs Containing HCM

Symbol Name Weight Mer Price(Change) Market Cap
AXJV iShares Edge MSCI Min Vol.. 0.00 % 0.35 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.66% 38% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.66% 38% F 19% F
Trailing 12 Months  
Capital Gain -66.66% 50% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.66% 50% F 25% F
Trailing 5 Years  
Capital Gain -43.37% 64% D 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.37% 62% D- 23% F
Average Annual (5 Year Horizon)  
Capital Gain 1.27% 56% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.27% 56% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 33.83% 75% C 48% F
Risk Adjusted Return 3.76% 59% F 41% F
Market Capitalization 2.33B 96% A 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.69 45% F 46% F
Price/Book Ratio 2.33 49% F 37% F
Price / Cash Flow Ratio -11.39 88% B+ 79% C+
EV/EBITDA -6.47 85% B 82% B-
Management Effectiveness  
Return on Equity -21.44% 66% D 35% F
Return on Invested Capital -44.63% 42% F 22% F
Return on Assets -19.57% 44% F 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.34 65% D 61% D-
Short Percent 1.90% 78% C+ 62% D-
Beta 0.71 74% C 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector